Plasma HSP90α Levels Used for Detection of Hepatocellular Carcinoma
By LabMedica International staff writers Posted on 14 Jan 2020 |
Image: The Roche cobas electro-chemiluminescence immunoassay kit for alpha-fetoprotein (AFP) (Photo courtesy of Toliopoulos Diagnostics).
Liver cancer is composed mostly of primary liver cancers and secondary liver cancers. Hepatocellular carcinoma (HCC), as the major type of primary liver cancer, is the fifth most common tumor worldwide and the third leading cause of cancer mortality, responsible for 745,500 cancer deaths annually.
HCC screening is based on measurement of serum alpha-fetoprotein (AFP) as well as imaging technologies and histology. Heat shock protein 90 (HSP90) is an evolutionarily highly conserved intracellular molecular chaperone that is usually induced in response to cellular stress and therefore HSP90 is a potential biomarker for tumor diagnosis and prognosis.
Scientists at the Guangxi Medical University (Nanning, China) enrolled from January 1, 2018 to February 28, 2019, a total of 801 liver disease patients in the Hepatobiliary Surgery Department of the Affiliated Tumor Hospital of Guangxi Medical University. The subjects included were 659 HCC patients, 114 secondary hepatic carcinoma (SHC) patients and 28 patients with hepatic hemangioma (HH).
The levels of plasma HSP90α were measured by using the enzyme-linked immunosorbent assay (ELISA) kit for HSP90α protein (Yantai Protgen Biotechnology Development Co. Ltd, Yantai, China). The optical density was measured by using a spectrophotometer at 450 nm for the detection wavelength with 620 nm as the reference wavelength. The levels of serum AFP were measured using Cobas electro-chemiluminescence immunoassay kits (Roche Diagnostics, Mannheim, Germany).
The medical team reported that the levels of plasma HSP90α in HCC patients were significantly higher (144.08 ± 4.98 ng/mL) than in healthy donors (46.81 ± 1.11 ng/mL) and in patients with hepatic hemangioma (61.56 ± 8.20 ng/mL) or SHC (111.96 ± 10.08 ng/mL). The levels were associated with age, Barcelona Clinical Liver Cancer (BCLC) stage, levels of AFP, tumor size, tumor number, portal vein tumor thrombus (PVTT), extrahepatic metastasis (EHM), and Child-Pugh stage in the HCC cohort. In addition, the levels of plasma HSP90α showed an upward trend along with the progression of the BCLC stage. The combination of HSP90α and AFP significantly improved the diagnostic efficiency for HCC patients.
The authors concluded that the levels of plasma HSP90α in healthy donors, benign liver tumor cohort, SHC cohort and HCC cohort showed a statistically significant increasing trend in this study. The combination of HSP90α and AFP significantly improved the diagnostic efficiency for HCC patients and these simple tests can be useful in both rural and cosmopolitan settings. The study was published on January 2, 2020 in the journal BMC Cancer.
Related Links:
Guangxi Medical University
Yantai Protgen Biotechnology Development Co. Ltd
Roche Diagnostics
HCC screening is based on measurement of serum alpha-fetoprotein (AFP) as well as imaging technologies and histology. Heat shock protein 90 (HSP90) is an evolutionarily highly conserved intracellular molecular chaperone that is usually induced in response to cellular stress and therefore HSP90 is a potential biomarker for tumor diagnosis and prognosis.
Scientists at the Guangxi Medical University (Nanning, China) enrolled from January 1, 2018 to February 28, 2019, a total of 801 liver disease patients in the Hepatobiliary Surgery Department of the Affiliated Tumor Hospital of Guangxi Medical University. The subjects included were 659 HCC patients, 114 secondary hepatic carcinoma (SHC) patients and 28 patients with hepatic hemangioma (HH).
The levels of plasma HSP90α were measured by using the enzyme-linked immunosorbent assay (ELISA) kit for HSP90α protein (Yantai Protgen Biotechnology Development Co. Ltd, Yantai, China). The optical density was measured by using a spectrophotometer at 450 nm for the detection wavelength with 620 nm as the reference wavelength. The levels of serum AFP were measured using Cobas electro-chemiluminescence immunoassay kits (Roche Diagnostics, Mannheim, Germany).
The medical team reported that the levels of plasma HSP90α in HCC patients were significantly higher (144.08 ± 4.98 ng/mL) than in healthy donors (46.81 ± 1.11 ng/mL) and in patients with hepatic hemangioma (61.56 ± 8.20 ng/mL) or SHC (111.96 ± 10.08 ng/mL). The levels were associated with age, Barcelona Clinical Liver Cancer (BCLC) stage, levels of AFP, tumor size, tumor number, portal vein tumor thrombus (PVTT), extrahepatic metastasis (EHM), and Child-Pugh stage in the HCC cohort. In addition, the levels of plasma HSP90α showed an upward trend along with the progression of the BCLC stage. The combination of HSP90α and AFP significantly improved the diagnostic efficiency for HCC patients.
The authors concluded that the levels of plasma HSP90α in healthy donors, benign liver tumor cohort, SHC cohort and HCC cohort showed a statistically significant increasing trend in this study. The combination of HSP90α and AFP significantly improved the diagnostic efficiency for HCC patients and these simple tests can be useful in both rural and cosmopolitan settings. The study was published on January 2, 2020 in the journal BMC Cancer.
Related Links:
Guangxi Medical University
Yantai Protgen Biotechnology Development Co. Ltd
Roche Diagnostics
Latest Pathology News
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases
- Bioinformatics Tool to Identify Chromosomal Alterations in Tumor Cells Can Improve Cancer Diagnosis
- Coin-Sized Device Rapidly Isolates Blood Plasma for Quicker and More Precise Clinical Diagnoses